Patents Assigned to Henry Ford Health System
  • Publication number: 20210213050
    Abstract: Described herein is a method for removing unwanted calcium hydroxylapatite or another calcium salt deposited by injection cutaneously in a subject, the method comprises administering an effective amount of a composition containing sodium thiosulfate to the deposited calcium hydroxylapatite or another calcium salt using a therapeutically effective regimen to diminish and or remove the amount of unwanted calcium hydroxylapatite or another calcium salt.
    Type: Application
    Filed: February 5, 2019
    Publication date: July 15, 2021
    Applicant: HENRY FORD HEALTH SYSTEM
    Inventor: David M. OZOG
  • Patent number: 11020488
    Abstract: Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 1, 2021
    Assignees: The Regents of the University of California, Henry Ford Health System
    Inventors: Phillip Crews, Frederick A. Valeriote, Sheng Lin, Erin P. McCauley, Nicholas Lorig-Roach, Karen Tenney
  • Patent number: 10916349
    Abstract: A method for determining risk of an adverse event, such as thrombosis or a required intervention, associated with a vascular access includes receiving hemodialysis treatment data associated with the vascular access, deriving a plurality of selected risk factors from the hemodialysis treatment data, evaluating the plurality of selected risk factors over a time period, assigning raw scores to each selected risk factor based on its values over the time period, summing the raw scores for the plurality of selected risk factors to determine a cumulative raw score, and correlating the cumulative raw score with a level of risk of an adverse event associated with the vascular access.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: February 9, 2021
    Assignee: Henry Ford Health System
    Inventors: John Kennedy, Brad Astor, Jeffrey J. Sands, Helen Kimball Hirschman, Douglas Curry, Stanley Frinak, Gerard Zasuwa, Jerry Yee, Anatole Besarab, Lalathaksha Kumbar
  • Publication number: 20210017602
    Abstract: Systems and methods to diagnose sarcoidosis are described. In addition to diagnosing sarcoidosis, the systems and methods can distinguish sarcoidosis from tuberculosis. Further disclosed is a cDNA library and methods of its use for reliably identifying sarcoidosis markers.
    Type: Application
    Filed: August 3, 2020
    Publication date: January 21, 2021
    Applicants: Wayne State University, Henry Ford Health System
    Inventors: Lobelia Samavati, Harvinder S. Talwar, Rita Rosati, Felix Fernandez-Madrid, Jia Li
  • Patent number: 10881461
    Abstract: A method of analyzing a hollow anatomical structure of interest for percutaneous implantation. The method comprises acquiring image data of an anatomical region of interest that includes the anatomical structure of interest, and generating a segmented model of the anatomical region of interest using the acquired image data. The method further comprises obtaining image(s) of the anatomical structure of interest by sectioning out intervening anatomical structures from the segmented model thereof, identifying one or more pertinent landmarks of the anatomical structure of interest in the acquired image(s), and measuring at least one of a circumference, a maximal diameter, or a minimal diameter of one or more features of the anatomical structure of interest contained in the acquired image(s) to determine an anatomical structure size. The method still further comprises reconciling the anatomical structure size and an implant size.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 5, 2021
    Assignee: Henry Ford Health System
    Inventors: Dee Dee Wang, William O'Neill, Eric Myers, Michael Forbes
  • Publication number: 20200367750
    Abstract: A system for monitoring an ablation procedure in a target tissue includes a first light source for delivering light to the target tissue to generate photoacoustic signals and a second light source for delivering light to the target tissue for ablation therapy. The system further includes a beam mixer for receiving light from the first and second light sources to create a combined light beam. An ablation catheter including a single optical fiber receives the combined light beam from the beam mixer, wherein the combined light beam is emitted from a tip of the ablation catheter to perform simultaneous ablation therapy and photoacoustic monitoring of the ablation procedure in the target tissue in real time.
    Type: Application
    Filed: February 1, 2019
    Publication date: November 26, 2020
    Applicants: HENRY FORD HEALTH SYSTEM, WAYNE STATE UNIVERSITY
    Inventors: Mohammad MEHRMOHAMMADI, Loay KABBANI, Nicole A. KENNEDY, Yan YAN
  • Publication number: 20200360462
    Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: November 19, 2020
    Applicants: Stealth Bio Therapeutics Corp, Henry Ford Health Systems
    Inventors: D. Travis Wilson, Hani N. Sabbah
  • Patent number: 10792104
    Abstract: A method for selecting a medical device for use in the performance of a medical procedure. The method comprises acquiring image data relating to an anatomical region of interest of a patient's body and generating a multi-dimensional depiction of the anatomical region of interest using the acquired image data. The method further comprises defining a plurality of points relative to the multi-dimensional depiction, determining one or more measurements based on the defined plurality of points, and then selecting a medical device to be used based on the determined measurements.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 6, 2020
    Assignee: Henry Ford Health System
    Inventors: Dee Dee Wang, Michael Forbes, Eric Myers, William O'Neill
  • Patent number: 10781489
    Abstract: Systems and methods to diagnose sarcoidosis are described. In addition to diagnosing sarcoidosis, the systems and methods can distinguish sarcoidosis from tuberculosis. Further disclosed is a cDNA library and methods of its use for reliably identifying sarcoidosis markers.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 22, 2020
    Assignees: WAYNE STATE UNIVERSITY, HENRY FORD HEALTH SYSTEM
    Inventors: Lobelia Samavati, Harvinder S. Talwar, Rita Rosati, Felix Fernandez-Madrid, Jia Li
  • Publication number: 20200138293
    Abstract: A system for characterization of a brain tissue sample includes a laser having an excitation fiber and a probe coupled to the excitation fiber for irradiating the brain tissue sample with light at an excitation wavelength. The probe further includes a plurality of return fibers for receiving light scattered from the brain tissue sample, wherein each return fiber includes a microfilter that permits light to pass for a different, spaced apart marker region. A Raman spectrometer is in communication with the plurality of return fibers, and a processor is in communication with the Raman spectrometer for analyzing Raman spectra within the marker regions to identify a tissue type of the brain tissue sample as one of normal white matter brain tissue, normal grey matter brain tissue, brain tumor tissue, infiltrating tumor tissue, and necrotic tissue.
    Type: Application
    Filed: April 20, 2018
    Publication date: May 7, 2020
    Applicants: HENRY FORD HEALTH SYSTEM, WAYNE STATE UNIVERSITY
    Inventors: Gregory William AUNER, Michelle BRUSATORI, Steven N. KALKANIS, Lisa SCARPACE
  • Patent number: 10639296
    Abstract: Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 5, 2020
    Assignee: Henry Ford Health System
    Inventors: Jae Ho Kim, Stephen L. Brown, Andrew Kolozsvary
  • Patent number: 10588697
    Abstract: A method for evaluating the placement of a prosthetic heart valve in a structure of interest. The method comprises acquiring one or more depictions of an anatomical region of interest that includes the structure of interest, wherein each depiction shows the structure of interest and/or the blood pool volume of the left ventricular outflow tract (LVOT) of the patient's heart. The method further comprises designating one or more positions in at least one of the one or more depictions wherein each position corresponds to a respective position in the structure of interest at which the prosthetic valve may be placed. The method still further comprises predicting, for each of the one or more designated positions, an amount of blood flow obstruction through the LVOT of the patient's heart that would occur if the prosthetic valve was to be placed at a corresponding position in the structure of interest.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 17, 2020
    Assignee: Henry Ford Health System
    Inventors: Dee Dee Wang, William O'Neill, Eric Myers, Michael Forbes
  • Patent number: 10537718
    Abstract: Technology disclosed herein provides a reduced transition between the edge of a rigid vascular dilator and the distal edge of the accompanying introducer sheath. Disclosed dilators can be segmented into two or more primarily longitudinally extending parts, can have rigid circumferential or semi-circumferential leading shoulders to minimize the transition between the dilator and the sheath edge, and can contain internal recesses to allow sequential retraction of segments once the introducer sheath is delivered to a target chamber. With this technology, vascular introducer sheaths can be introduced percutaneously into a broad range of diseased target vessels and chambers with reduced damage to the wall of the vessel or chamber, and with reduced damage to the distal end of the introducer sheath.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: January 21, 2020
    Assignees: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Henry Ford Health System
    Inventors: Robert Jay Lederman, Ozgur Kocaturk, Adam Brett Greenbaum
  • Publication number: 20200001111
    Abstract: The present invention relates to the treatment of cancer by irradiation by high energy photons, wherein the cancer has been infused with a heavy metal. The invention further relates to the use of pair-production for increased cancer cell destruction.
    Type: Application
    Filed: February 15, 2018
    Publication date: January 2, 2020
    Applicant: Henry Ford Health System
    Inventors: Derek M. ISROW, Stephen L. BROWN, Jae Ho KIM, Indrin J. CHETTY, Panagiotis TSIAMAS
  • Publication number: 20190381233
    Abstract: A method and a system are provided for detecting a condition indicative of a dislodged needle in a hemodialysis procedure. A venous return pressure for a patient undergoing dialysis is measured. The venous return pressure is analyzed via a controller, and an intravascular blood pressure in proximity to a location of needle insertion into the patient is derived. A lower limit is calculated as a function of the intravascular blood pressure via the controller. An average of the venous return pressure is calculated via the controller during a predetermined time window. The average is compared to the lower limit via the controller, and if the average is within a specified range of the lower limit, the controller determines that a condition indicative of a dislodged needle is present.
    Type: Application
    Filed: September 19, 2017
    Publication date: December 19, 2019
    Applicant: HENRY FORD HEALTH SYSTEM
    Inventors: Stanley FRINAK, Gerard ZASUWA, Jerry YEE, Anatole BESARAB
  • Publication number: 20190314566
    Abstract: A method of detecting intravascular volume depletion in a patient during a hemodialysis session includes measuring venous drip pressure for the patient. With a computer-driven analyzer, the method further includes analyzing the venous drip pressure and automatically and continuously determining a venous access pressure in proximity to a location of needle insertion into a vascular access site of the patient, wherein changes in venous access pressure are representative of changes in intravascular blood pressure. Using the analyzer, the method further includes comparing the venous access pressure to a standard and, if the venous access pressure is outside of a defined range of the standard, determining with the analyzer that the patient is experiencing intravascular volume depletion during the hemodialysis session.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 17, 2019
    Applicant: HENRY FORD HEALTH SYSTEM
    Inventors: Gerard ZASUWA, Stanley FRINAK, Jerry YEE, Anatole BESARAB, John B. KENNEDY, Jeffrey J. SANDS
  • Patent number: 10307575
    Abstract: The procedure to place antegrade hemodynamic support (AHS) combine currently available procedures and devices in a unique fashion to solve a significant problem for patients who need large bore hemodynamic support. The AHS procedure involves delivering an AHS device or a catheter connected to an AHS device to a patient's aorta in an antegrade fashion, alleviating the workload on the patient's heart and supporting the patient hemodynamically to maintain normal functions of the body organs.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: June 4, 2019
    Assignee: Henry Ford Health System
    Inventor: Khaldoon Alaswad
  • Patent number: 10308959
    Abstract: Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase neuronal differentiation, oligodendrocyte differentiation, or neurological outcome or function in a patient in need thereof. Some embodiments also comprise the administration a composition comprising a pharmaceutically effective amount of one or more of a group comprising microRNA-146a, exosomes comprising microRNA-146a, a promoter of microRNA-146a expression, a microRNA-146a thymosin beta 4, and a phosphodiesterase 5 inhibitor to treat neurological conditions, diseases, or injuries in mammals, including in human beings.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: June 4, 2019
    Assignee: Henry Ford Health System
    Inventors: Xianshuang Liu, Zhenggang Zhang, Michael Chopp, Lei Wang, Benjamin A. L. Buller
  • Patent number: 10260106
    Abstract: A method for diagnosing and treating prostate cancer in a human subject is provided, the method comprises: a. providing a sample of prostate tissue, blood, or urine from the subject; b. determining the level of expression of SEQ ID NO: 1 and the expression of SEQ ID NO: 5 in the sample, wherein an increased level of expression of SEQ ID NO:1 and a reduced level of expression of SEQ ID NO: 5 in the sample is indicative of a diagnosis that the subject has prostate cancer; and c. administering a therapeutically effective prostate cancer treatment selected from the group consisting of an androgen receptor (AR)-targeted therapy, an antimicrotubule agent, an alkylating agent and an anthracenedione to the subject to treat the prostate cancer in the human subject diagnosed with prostate cancer.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 16, 2019
    Assignee: Henry Ford Health System
    Inventors: G. Prem-Veer Reddy, Mani Menon
  • Patent number: D844145
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: March 26, 2019
    Assignee: Henry Ford Health System
    Inventor: Fuxiang Zhang